GeneDx released FY2025 Q2 earnings on July 29 Pre-Market (EST), actual revenue USD 102.69 M (forecast USD 85.58 M), actual EPS USD 0.36 (forecast USD -0.14)

Brief Summary

GeneDx reported Q2 2025 earnings with revenue of $103 million and EPS of $0.36, both exceeding market expectations.

Impact of The News

GeneDx’s Q2 2025 financial results demonstrated a robust performance, significantly surpassing market expectations. The company reported a revenue of $103 million, outpacing the expected $85.58 million, and an EPS of $0.36, far exceeding the anticipated -$0.14 Reuters+ 2. This marks the fourth consecutive profitable quarter for the company, highlighting the strong performance driven by its core business Reuters. GeneDx’s quarterly net income was $10.81 million, consistent with the reported EPS Reuters.

Comparing to peers, GeneDx’s revenue growth of 49% year-over-year is substantial and indicative of its growing market presence Reuters. The company has also updated its full-year revenue guidance upward to a range of $400 million to $415 million, from the previous $360 million to $375 million, signaling confidence in continued strong performance Reuters. Furthermore, the company expects a growth of 48%-52% in its exome and genome products and aims for an adjusted gross margin of 68%-71% for 2025 Reuters.

The impressive financial results and the upward revision of the full-year guidance suggest a positive business trajectory for GeneDx. Investors can reasonably anticipate sustained revenue growth and profitability in the forthcoming periods, driven by the company’s strong core business and strategic focus on high-growth genomic products.